Gyre Therapeutics FY2025 revenue up 10% to $116.6M; net income down; guides FY2026 lower

GYRE THERAPEUTICS, INC.

Full-year 2025 revenue $116.6M (+10.2% YoY); net income $9.9M vs $17.9M; non-GAAP adj. net income $18.9M vs $16.9M.
Q4 2025 revenue $37.2M (+33.3% YoY); net loss $1.4M vs income $0.6M; non-GAAP adj. net income $4.3M vs $1.1M.
FY2026 revenue guidance $100.5M–$111.0M, a decline of 4.8%–13.8% vs 2025, citing regulatory priorities and market dynamics.
Agreed to acquire Cullgen in ~$300M all-stock deal; transaction expected to close Q2 2026, adding protein degrader platform.
Hydronidone NDA for conditional approval in China (CHB fibrosis) planned H1 2026; U.S. IND for MASH fibrosis targeted in 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GYRE THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2025 results: revenue $116.6 million. Guidance reaffirmed.

Period: the fourth quarter and full year ended December 31, 2025
Revenue: $116.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-102700

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.